BennuBio, founded with the mission to revolutionize cellular analysis, focuses on developing advanced flow cytometry devices. Their core product, the Velocyt®, offers unprecedented 3D multicellular model system analysis with high throughput, enabling significant biological insights. The company's vision is to unlock the untapped potential of flow cytometry for various applications, catering to researchers and clinicians in the biomedical field.
Notable figures associated with BennuBio include leading scientists and industry experts who drive innovation. The company has attracted significant investment from venture capital firms focused on cutting-edge medical technologies. Key achievements include the development of the Velocyt®, which delivers volumetric sample rates up to 100 times faster than traditional methods and can handle a wide range of particle sizes. BennuBio's impact lies in its ability to enhance research capabilities and clinical diagnostics, pushing the boundaries of cellular analysis.
